BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25599782)

  • 1. The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation.
    Hakim GD; Akarsu M; Karademir S; Unek T; Astarcıoğlu İ
    Turk J Gastroenterol; 2014 Dec; 25(6):685-9. PubMed ID: 25599782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation.
    Stravitz RT; Shiffman ML; Kimmel M; Puri P; Luketic VA; Sterling RK; Sanyal AJ; Cotterell AH; Posner MP; Fisher RA
    Liver Int; 2012 Aug; 32(7):1138-45. PubMed ID: 22348467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
    Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
    Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
    Idilman R; Akyildiz M; Keskin O; Gungor G; Yilmaz TU; Kalkan C; Dayangac M; Cinar K; Balci D; Hazinedaroglu S; Tokat Y
    Clin Transplant; 2016 Oct; 30(10):1216-1221. PubMed ID: 27409074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.
    Teperman LW; Poordad F; Bzowej N; Martin P; Pungpapong S; Schiano T; Flaherty J; Dinh P; Rossi S; Subramanian GM; Spivey J
    Liver Transpl; 2013 Jun; 19(6):594-601. PubMed ID: 23447407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation.
    McGonigal KH; Bajjoka IE; Abouljoud MS
    Pharmacotherapy; 2013 Sep; 33(9):e170-6. PubMed ID: 23744810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
    Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
    Lee YB; Jung EU; Kim BH; Lee JH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Lee DH; Cho EJ; Yu SJ; Park SJ; Kim YJ; Park JW; Lee YJ; Kim CM; Yoon JH; Kim CY; Lee HS
    Antimicrob Agents Chemother; 2015 Feb; 59(2):972-8. PubMed ID: 25421484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.
    Greenup AJ; Tan PK; Nguyen V; Glass A; Davison S; Chatterjee U; Holdaway S; Samarasinghe D; Jackson K; Locarnini SA; Levy MT
    J Hepatol; 2014 Sep; 61(3):502-7. PubMed ID: 24801414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
    Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
    Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation.
    Tanaka T; Renner EL; Selzner N; Therapondos G; Lilly LB
    Can J Gastroenterol Hepatol; 2014 Jan; 28(1):41-4. PubMed ID: 24212911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
    Neff GW; Kemmer N; Kaiser TE; Zacharias VC; Alonzo M; Thomas M; Buell J
    Dig Dis Sci; 2007 Oct; 52(10):2497-500. PubMed ID: 17404847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
    Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
    Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.
    Cholongitas E; Papatheodoridis GV
    Am J Transplant; 2013 Feb; 13(2):353-62. PubMed ID: 23137006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.